加载页面时好像出了点问题.
我们的团队已经注意到了，但如果问题仍然存在，请使用电子邮件支持小工具联系我们。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 0.0x - 0.0x | 0.0x |
| Selected Fwd P/E Multiple | 0.0x - 0.0x | 0.0x |
| Fair Value | 0.021$ - 0.023$ | 0.022$ |
| Upside | 39.5% - 54.2% | 46.9% |
| Benchmarks | - | Full Ticker |
| Ionis Pharmaceuticals, Inc. | - | NasdaqGS:IONS |
| Ardelyx, Inc. | - | NasdaqGM:ARDX |
| BioMarin Pharmaceutical Inc. | - | NasdaqGS:BMRN |
| Apollomics, Inc. | - | NasdaqCM:APLM |
| Keros Therapeutics, Inc. | - | NasdaqGM:KROS |
| Yield10 Bioscience, Inc. | - | OTCPK:YTEN.Q |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| IONS | ARDX | BMRN | APLM | KROS | YTEN.Q | |||
| NasdaqGS:IONS | NasdaqGM:ARDX | NasdaqGS:BMRN | NasdaqCM:APLM | NasdaqGM:KROS | OTCPK:YTEN.Q | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | -23.9% | 40.8% | 154.6% | 85.3% | -22.5% | 10.9% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -37.4% | -888.5% | 13.5% | -416816.0% | -144421.8% | -3739.9% | ||
| Prior Fiscal Year | -46.5% | -53.1% | 6.9% | -74554.5% | -101319.2% | -3014.7% | ||
| Latest Fiscal Year | -64.4% | -11.7% | 15.0% | -21023.3% | -5277.5% | -24091.7% | ||
| Latest Twelve Months | -64.4% | -11.7% | 15.0% | -2718.4% | -5277.5% | -1693.6% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -10.1x | -44.5x | 19.3x | 0.2x | 0.5x | -0.2x | ||
| Price / LTM Sales | 7.1x | 3.7x | 4.9x | 4.4x | 125.6x | 0.0x | ||
| LTM P/E Ratio | -11.1x | -31.2x | 32.5x | -0.2x | -2.4x | 0.0x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -31.2x | -2.4x | 32.5x | |||||
| Historical LTM P/E Ratio | -2.2x | -0.7x | -0.2x | |||||
| Selected P/E Multiple | 0.0x | 0.0x | 0.0x | |||||
| (x) LTM Net Income | (13) | (13) | (13) | |||||
| (=) Equity Value | 0 | 0 | 0 | |||||
| (/) Shares Outstanding | 0.7 | 0.7 | 0.7 | |||||
| Implied Value Range | 0.02 | 0.02 | 0.02 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 0.02 | 0.02 | 0.02 | 0.02 | ||||
| Upside / (Downside) | 36.6% | 43.7% | 50.9% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | IONS | ARDX | BMRN | APLM | KROS | YTEN.Q | |
| Value of Common Equity | 5,006 | 1,201 | 13,637 | 9 | 447 | 0 | |
| (/) Shares Outstanding | 159.0 | 238.4 | 190.8 | 1.1 | 40.6 | 0.7 | |
| Implied Stock Price | 31.49 | 5.04 | 71.48 | 8.16 | 11.01 | 0.02 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 31.49 | 5.04 | 71.48 | 8.16 | 11.01 | 0.02 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |